People who suffer from the autoimmune disease myasthenia gravis experience muscle weakness that can affect any of the muscles we use to blink, smile or even move our body around. Researchers have ...

From the outside, a new store bearing the adidas Trefoil logo in Seoul’s Seongsu-dong stands out with its red-brick facade, ...

Collect data at scale for agents without being blocked Simulate user behavior using advanced browser tools Build agent applications with real-time and historical web data Unlock any scale with ...

Mooresville, NC, April 01, 2025 (GLOBE NEWSWIRE) -- Fundamental Global Inc. (Nasdaq: FGF, FGFPP) (the "Company” or "Fundamental Global”) today announced results for the fourth quarter and full year ...

The patient was diagnosed with hereditary ATTR-CM following genetic testing, which revealed the presence of a mutation in the TTR gene. Researchers from India and the US presented the case of a ...

“Variant ATTR-CM patients’ condition often presents at an earlier age and progresses more rapidly than patients with wild-type disease, which translates into a worse prognosis in many such patient ...

ELLABELL, Georgia — “My story begins just down the road, having been born and raised right here in Ellabell. As a young girl, I used to ride four-wheelers in the woods near the Metaplant ...

“There is significant need for new treatment options for ATTR-CM, a progressive, fatal disease, worldwide. This latest approval marks an important development for the ATTR-CM community, and we ...

A case report by Japanese authors demonstrates the strengths of tafamidis as a long-term drug in managing ATTR-CM. Transthyretin amyloid cardiomyopathy (ATTR-CM) raises the risk of early mortality ...

Alnylam Pharmaceuticals’ Amvuttra (vutrisiran) has been approved by the Food and Drug Administration (FDA) to treat transthyretin amyloid cardiomyopathy (ATTR-CM), a potentially fatal disease of the ...

[This short story traces an imaginary future history of the US.] The “United States of America” lasted 12 centuries, although it has long been based primarily in Europe. Today, the last US president, ...

Despite growing competition in the transthyretin amyloid cardiomyopathy (ATTR-CM) field, Alnylam is hoping its RNA interference approach can set it apart from its peers. And now, the Massachusetts ...